Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9882489 | 1.00 | PBRM1 (0.34) | PBRM1MALT1HTR2BLMNAMAPT | |
| SCHEMBL8515666 | 0.85 | PBRM1 (0.40) | PBRM1MALT1LMNAMAPTHTT | |
| SCHEMBL9882483 | 0.85 | PBRM1 (0.40) | PBRM1MALT1LMNAMAPTHTT | |
| SCHEMBL12489867 | 0.79 | PBRM1 (0.38) | PBRM1MALT1MAPTHTT | |
| SCHEMBL8535160 | 0.79 | PBRM1 (0.33) | PBRM1MALT1LMNAMAPTHTT | |
| SCHEMBL12489864 | 0.79 | PBRM1 (0.38) | PBRM1MALT1MAPTHTT | |
| SCHEMBL9882537 | 0.79 | PBRM1 (0.33) | PBRM1MALT1LMNAMAPTHTT | |
| SCHEMBL8512844 | 0.74 | PPIB (0.38) | MALT1HTR2BMAPT | |
| SCHEMBL8512845 | 0.74 | PPIB (0.38) | MALT1HTR2BMAPT | |
| SCHEMBL8532278 | 0.74 | BACE1 (0.33) | PBRM1LMNAMAPTHTTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012071458-A1 | HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | PBRM1 3853/4885MALT1 4452/4885HTR2B 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.